Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. CO- DEVELOPMENT AND...Co-Development and Commercialization Agreement • May 8th, 2019 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into and made effective as of February 22, 2019 (the “Effective Date”) by and between Editas Medicine, Inc., a Delaware corporation (“Editas”) and Allergan Sales, LLC, a Delaware limited liability company (“Allergan”). Editas and Allergan are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
